Min Li1, Jiarong Lan2, Feixia Dong3, Peixin Duan4. 1. Department of Endocrine, Huzhou Hospital of Traditional Chinese Medicine Affiliated, Zhejiang University of Traditional Chinese Medicine, Huzhou, 313000, Zhejiang, China. 2. Department of Nephrology, Huzhou Hospital of Traditional Chinese Medicine Affiliated, Zhejiang University of Traditional Chinese Medicine, Huzhou, 313000, Zhejiang, China. 3. Department of Nephrology, Wenzhou Hospital of Traditional Chinese Medicine Affiliated, Zhejiang University of Traditional Chinese Medicine, Wenzhou, 325000, Zhejiang, China. 4. Department of Nephrology, Changxing People's Hospital, Huzhou, 313100, Zhejiang, China. yydcx1213@126.com.
Abstract
PURPOSE: To meta-statistically compare the efficiency of hypoxia-induced factor prolyl hydroxylase inhibitor on hemoglobin, ferritin, hepcidin rate, and adverse events. METHODS: A systematic identification of literature was performed according to PRISMA guidelines on 4 academic databases: MEDLINE, Scopus, EMBASE, and CENTRAL. A meta-analysis evaluating the influence of hypoxia-induced factors was performed for patients undergoing/not undergoing hemodialysis. The analysis evaluated the efficacy of hypoxia-induced factors on hemoglobin, ferritin, hepcidin rate, and the number of adverse events. RESULTS: Out of 1052 records, 15 articles including 2045 patients (mean age 62.1 ± 5.4 years) were included in this review. The systematic review presents a 1a level of evidence supporting the use of hypoxia-induced factor for mediating anemia in patients with chronic kidney disease. The meta-analysis reveals medium to large beneficial effects of the hypoxia-induced factor on hemoglobin rate for patients receiving (0.72) and not receiving (1.04) hemodialysis. Moreover, the administration of hypoxia-induced factors was reported to reduce ferritin rate and the hepcidin rate, and the number of adverse events in patients with chronic kidney disease. CONCLUSION: The current meta-analysis recommends the use of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease.
PURPOSE: To meta-statistically compare the efficiency of hypoxia-induced factor prolyl hydroxylase inhibitor on hemoglobin, ferritin, hepcidin rate, and adverse events. METHODS: A systematic identification of literature was performed according to PRISMA guidelines on 4 academic databases: MEDLINE, Scopus, EMBASE, and CENTRAL. A meta-analysis evaluating the influence of hypoxia-induced factors was performed for patients undergoing/not undergoing hemodialysis. The analysis evaluated the efficacy of hypoxia-induced factors on hemoglobin, ferritin, hepcidin rate, and the number of adverse events. RESULTS: Out of 1052 records, 15 articles including 2045 patients (mean age 62.1 ± 5.4 years) were included in this review. The systematic review presents a 1a level of evidence supporting the use of hypoxia-induced factor for mediating anemia in patients with chronic kidney disease. The meta-analysis reveals medium to large beneficial effects of the hypoxia-induced factor on hemoglobin rate for patients receiving (0.72) and not receiving (1.04) hemodialysis. Moreover, the administration of hypoxia-induced factors was reported to reduce ferritin rate and the hepcidin rate, and the number of adverse events in patients with chronic kidney disease. CONCLUSION: The current meta-analysis recommends the use of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease.
Entities:
Keywords:
Anemia; Chronic renal insufficiency; Hemodialysis; Hypoxia-induced factor; Iron metabolism
Authors: N C van der Weerd; M P C Grooteman; M J Nubé; P M ter Wee; D W Swinkels; C A J M Gaillard Journal: Neth J Med Date: 2015-03 Impact factor: 1.422
Authors: Jerome L Abramson; Claudine T Jurkovitz; Viola Vaccarino; William S Weintraub; William McClellan Journal: Kidney Int Date: 2003-08 Impact factor: 10.612
Authors: Nathan R Hill; Samuel T Fatoba; Jason L Oke; Jennifer A Hirst; Christopher A O'Callaghan; Daniel S Lasserson; F D Richard Hobbs Journal: PLoS One Date: 2016-07-06 Impact factor: 3.240
Authors: Manjula Kurella Tamura; Eric Vittinghoff; Jingrong Yang; Alan S Go; Stephen L Seliger; John W Kusek; James Lash; Debbie L Cohen; James Simon; Vecihi Batuman; Juan Ordonez; Gail Makos; Kristine Yaffe Journal: BMC Nephrol Date: 2016-01-28 Impact factor: 2.388